CTD²: Cancer Target Discovery and Development

The Cancer Target Discovery and Development (CTD²) Network, a functional genomics initiative, bridges the gap between cancer genomics and biology. The Network aims to understand how tumor heterogeneity leads to drug resistance in order to develop optimal combinations of chemotherapy or small molecules in combination with immunotherapy.

Banner for CTD squared program. Links to CTD squared program page

Last updated: January 03, 2019

News & Publications

View In the News Page

CTD²

January 15, 2020

Twist1-Induced Epithelial Dissemination Requires Prkd1 Signaling.

Dissemination is an essential early step in metastasis but its molecular basis remains incompletely understood. To define the essential targetable effectors of this process, we developed a 3D mammary epithelial culture model, in which dissemination is induced by overexpression of the...

Proposed model of ST-mediated transformation

CTD²

January 08, 2020

STRIPAK directs PP2A activity toward MAP4K4 to promote oncogenic transformation of human cells.*

Alterations involving serine-threonine phosphatase PP2A subunits occur in a range of human cancers and partial loss of PP2A function contributes to cell transformation. Displacement of regulatory B subunits by the SV40 Small T antigen (ST) or mutation/deletion of PP2A subunits alters the...

Experimental settings and reagents used in the experimental pipelines underlying the two compared data sets.

CTD²

December 20, 2019

Agreement between two large pan-cancer CRISPR-Cas9 gene dependency data sets.

Genome-scale CRISPR-Cas9 viability screens performed in cancer cell lines provide a systematic approach to identify cancer dependencies and new therapeutic targets. As multiple large-scale screens become available, a formal assessment of the reproducibility of these experiments becomes necessary...

Antibody-dependent cell-mediated cytotoxicity

CTD²

December 19, 2019

Pluripotent stem cell-derived NK cells with high-affinity non-cleavable CD16a mediate improved anti-tumor activity.

Antibody-dependent cellular cytotoxicity (ADCC) is a key effector mechanism of natural killer (NK) cells mediated by therapeutic monoclonal antibodies (mAbs). This process is facilitated by the Fc receptor CD16a on human NK cells. CD16a appears to be the only activating receptor on NK cells...

CTD²

December 05, 2019

Cooperative blockade of PKCα and JAK2 drives apoptosis in glioblastoma.

The mechanistic target of rapamycin (mTOR) signaling is dysregulated prominently in human cancers including glioblastoma, suggesting mTOR as a robust target for therapy. Inhibitors of mTOR have had limited success clinically however, in part because their mechanism of action is cytostatic rather...